The Mydrug Platform Trial: Efficacy and Safety of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Patients with Functionally High-Risk Multiple Myeloma
Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4434-4435
10.1182/blood-2022-163737